D Wilmore - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

D Wilmore

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Journal of the National Cancer Institute|September 7, 1988

Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic studyD R Spriggs, M L Sherman, H Michie, et al.

Cancer Treatment Reports|February 1, 1987

High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experienceK Antman, J P Eder, A Elias, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1986

High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trialW P Peters, J P Eder, W D Henner, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Journal of the National Cancer Institute|September 7, 1988

Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic studyD R Spriggs, M L Sherman, H Michie, et al.

Cancer Treatment Reports|February 1, 1987

High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experienceK Antman, J P Eder, A Elias, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1986

High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trialW P Peters, J P Eder, W D Henner, et al.

Pageof 2